Home > Analyse
Actualite financiere : Actualite bourse

Sanofi: Oddo confirms 'neutral' rating.

(CercleFinance.com) - In a report issued on Thursday morning, Oddo has renewed its "neutral" rating on the Sanofi stock, along with its target price of 81 euros, with the French pharmaceutical giant having requested the health authorities to update information provided to doctors and patients about its dengue vaccine, Dengvaxia, in countries where it has been approved.

Data at 6 years actually calls into question its benefits/risk profile and the broker expects the consensus to cut its estimate for turnover in 2020 by close to 300 million euros.

It highlights the financial consequences of this (EPS eventually down by 2%-3% over long term), as well as the group's image, with questions about Sanofi's residual capacity to innovate. This is quite rightly so: for people with no history of dengue fever, the analyses have revealed that over the longer term following vaccination, more severe cases of dengue fever could be seen if the in the event of exposure to the virus.

Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.